Thursday, 24 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 17, 2026

Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026

View original at finance.yahoo.com
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026 Data show long-term effectiveness of GARDASIL®9 and GARDASIL® 14 years and 18 years, respectively, following vaccination with 3 doses Data on certain HPV-related orophary…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Not all vulvar, vaginal, anal, oropharyngeal and other head and neck cancers are caused by HPV

    60% confidence

  • GARDASIL 9 and GARDASIL have not been demonstrated to provide protection against diseases caused by HPV types not covered by the vaccine or HPV types to which a person has previously been exposed through sexual activity

    60% confidence

  • Data on certain HPV-related oropharyngeal cancers highlight the importance of HPV vaccination in helping to prevent these cancers, which impact both women and men

    60% confidence

  • Nearly two decades after the U.S. FDA approval of GARDASIL in June 2006, we are proud to present these data for GARDASIL 9 and GARDASIL that reinforce the long-term effectiveness and importance of HPV vaccination for females ages 9 to 45 years, beginning in adolescence

    60% confidence

  • The duration of immunity of GARDASIL and a 2-dose schedule of GARDASIL 9 has not been established

    60% confidence

  • Results from studies show vaccine effectiveness for at least 14 years following 3 doses of the 9-valent vaccine, and vaccine effectiveness up to 18 years after 3 doses of the quadrivalent vaccine against HPV 16/18-related high-grade cervical disease

    60% confidence

  • GARDASIL 9 and GARDASIL do not eliminate the necessity for vaccine recipients to undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as recommended by a health care provider

    60% confidence

  • Data show long-term effectiveness of GARDASIL 9 and GARDASIL 14 years and 18 years, respectively, following vaccination with 3 doses

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026 — Source | Via News | ViaNews EU